Dry Eye

The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye should be conducted.

Lab TRIACTIV is powered by “advanced cationic liposomal technology” for dry eye relief.

Patients reported that Miebo significantly reduced overall symptoms severity at the primary endpoint of change from baseline in the severity of overall dry eye symptoms at day 7.

This program is in place for prescriptions of cyclosporine ophthalmic solution 0.1% (VEVYE, Harrow) and promises a $59 price tag per bottle, effective immediately.

Italian investigators reported that ocular surface conditions such as dry eye disease are key factors in perioperative outcomes, even when patients achieve 20/20 vision.

The new formula will help relieve temporary symptoms caused by dryness of the eye.

According to the company, the suffix “-mod” in urcosimod denotes its classification as a modulator of key inflammatory and neuropathic pathways.

Researchers conducted a study to characterize ophthalmic adverse events associated with cosmetics and personal care products that have been reported in the FDA CAERS database.

Alice T. Epitropoulos, MD, FACS, outlines her approach to managing evaporative dry eye. This includes diagnosing meibomian gland dysfunction, using thermal pulsation to clear gland blockages, and ensuring long-term results with advanced treatments and patient education.

Topline data results are expected in February 2025.

A study conducted with over 77,000 individuals found that alcohol consumption increased the risk of dry eye in women.

This action follows a consumer complaint of foreign material in a sealed single-use vial.

A look at the biggest news and advancements in ophthalmology in 2024.

A University of Colorado study links air pollution to increased ocular health issues, finding patient visits for irritation and allergies more than double during high particulate matter levels, emphasizing the need for proactive clinical strategies.

BostonSight’s pilot study, published in Clinical Ophthalmology, explores the use of PROSE scleral lenses as a drug delivery system for cyclosporine 0.05% in treating dry eye disease, showing promising symptom relief and tolerability.

The funding will primarily support advancement of Elate Ocular through its registration-enabling phase 3 clinical trials for dry eye disease.

Special circumstances must be considered for plateau dwellers, such as Tibetans, mountaineers, and garrison officers, who are exposed to low humidity, strong ultraviolet rays, cold and dry weather, and low pressure and hypoxia

A PDUFA decision date of April 2, 2025 has been assigned

Sun Pharmaceutical presented Phase 4 data at ESCRS 2024 showing that cyclosporine ophthalmic solution 0.09% significantly improves dry eye disease symptoms and corneal staining in patients inadequately controlled on Restasis, with positive results observed through 12 weeks of treatment.

Study highlights safety, efficacy of device in managing persistent DED.

Harrow announced that starting in January 2025, Vevye will be covered under key Medicare Part D formularies and across major insurance programs, expanding access to the dry eye disease treatment for millions of patients, particularly older adults.

Joanne F. Shen, MD, director of the dry eye clinic at Mayo Clinic's campus in Phoenix, Arizona, and a research team studied 35 patients treated with IPL/MGX. The team reviewed demographics, ocular histories, Standard Patient Evaluation of Eye Dryness 2 symptom survey scores, slit-lamp examinations and meibomian gland evaluations at baseline and at each visit before IPL/MGX treatments.

The authors reported significant variability in DED-related symptoms, with higher prevalence rates among university students and administrative workers.

John D. Sheppard, MD, MMSc, FACS, spoke with the Eye Care Network to provide some insight on post hoc analysis of the ESSENCE 1 trial dor dry eye disease.

The resubmission comes after receiving a Complete Response Letter at the end of 2023.